麻豆国产精品一二三在线观-麻豆国产精品一二三在线观看-麻豆国产精品一区二区-麻豆国产精品永久免费视频-麻豆国产巨作av剧情-麻豆国产蜜桃臀视频在线观看

以色列Pluristem Therapeutics Inc
luristem Therapeutics, Inc.從事間質(zhì)干細(xì)胞的生產(chǎn)技術(shù)的研究和開發(fā)，以及細(xì)胞療法的產(chǎn)品的商品化。 該公司正開發(fā)一個(gè)平臺(tái)，這樣設(shè)計(jì)是為了創(chuàng)建一個(gè)功能干細(xì)胞的生產(chǎn)系統(tǒng)，可以治療重癥血液，心血管疾病，自身免疫性和其它疾病。 它開發(fā)了PluriX Bioreactor系統(tǒng)，該系統(tǒng)的設(shè)計(jì)是一個(gè)系統(tǒng)的基質(zhì)干細(xì)胞的文化和襯底上，創(chuàng)建一個(gè)人工生理環(huán)境下，間質(zhì)干細(xì)胞可以生長和繁殖以外的人體無任何使用外源性生物制品或生物克隆。 該公司成立于2001年，前身是AI Software, Inc.，在2003年公司改名為Pluristem Life Systems, Inc.，后來在2007年11月又改名為Pluristem Therapeutics, Inc.，公司位于以色列的Haifa。

Pluristem Therapeutics Inc. (NASDAQ: PSTI; DAX: PJT) is a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products derived from human placenta, a non-controversial, non-embryonic, adult stem cell source. The (PLacental eXpanded) cell products are stored off-the-shelf, ready-to-use, and require no histocompatibility matching.

These placental adherent stromal cells (ASCs) are expanded in the Company's proprietary PluriXTM 3D bioreactor system, which provides a 3D microenvironment that enables large-scale growth of these cells without the need for supplemental growth factors or other exogenous materials. PLX cells are immune privileged, possess immunomodulatory properties, and are expanded in vitro without showing signs of phenotypic or karyotypic changes. Pluristem believes that the PLX cells?mechanism of action may be related to the secretion of cytokines and/or other potent immune modulators.

Pluristem's first product, PLX-PAD (for the treatment of Peripheral Artery Disease), received from the Food and Drug Administration (FDA) and the Paul Ehrlich Institute (PEI), the German competent authority in the European Union, clearance to begin a 揊irst-In-Human?placental-derived mesenchymal-like stromal cell clinical trial.

Pluristem has offices in the USA with research and manufacturing facilities in Israel.